As vaping continues to grow in popularity, it becomes increasingly critical to correct misconceptions about its safety and long-term effects.
Use of electronic cigarettes (e-cigarettes), or vaping, has drastically increased in recent years, primarily among young adults. About 1 in 5 young adults use e-cigarettes regularly, and 1 in 4 believe that e-cigarettes are harmless and nonaddictive.1
E-cigarettes aerosolize nicotine mixed with flavoring and preservative agents. Though combustible tobacco products, such as cigarettes and cigars, are widely recognized as causes of respiratory disease, e-cigarettes are often promoted as safe alternatives. However, studies show that vaping leads to chronic pulmonary inflammation, tissue damage, oxidative stress, and mucus hypersecretion.
A December 2019 study published in theAmerican Journal of Preventive Medicineshows the first population-based, longitudinal analysis of the relationship between e-cigarettes and respiratory disease. The researchers used data from 32,320 participants in the Population Assessment of Tobacco and Health (PATH) study, a national population-based study led by the NIH and FDA.2-3At baseline and over 2 years, researchers noted whether respondents had respiratory disease, used e-cigarettes, and/or used combustible tobacco products.
A number of subjects reported both respiratory disease and e-cigarette use at baseline. Even after controlling for confounding factors that included age, BMI, poverty level, and combustible tobacco smoking, there was a significant association between former or current e-cigarette use and the risk of respiratory disease.
Read the full article onPharmacy Times.
May Zhangis a 2022 PharmD Candidate at the University of Connecticut in Storrs.
REFERENCES